


Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 3 of 25

The following is a copy of the Claim Listing as submitted February 8, 2005, which  
superseded and replaced all previous Claim Listings:

### CLAIM LISTING

I. (Currently amended) A compound of formula I




formula I

wherein

R<sup>1</sup> is hydrogen or C<sub>1-6</sub>-alkyl;

R<sup>2</sup> is hydrogen or C<sub>1-6</sub>-alkyl;

L is



wherein R<sup>4</sup> is hydrogen or C<sub>1-6</sub> alkyl;

p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;

Attorney Docket No. 5573.210-US  
Application No. 09/356,313


August 10, 2007  
Page 4 of 25

r is 1;

the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

$R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

Q is  $>N-R^{13}$  or




wherein o is 0, 1 or 2;

T is  $-N(R^{15})(R^{16})$  or hydroxyl;

$R^{13}$ ,  $R^{15}$ , and  $R^{16}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

$R^{14}$  is hydrogen, aryl or hetaryl;

or L is



p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;

r is 0 or 1;


Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 5 of 25

the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

$R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

Q is  $>N-R^{13}$  or




wherein  $o$  is 0, 1 or 2;

T is  $-N(R^{15})(R^{16})$  or hydroxyl;

$R^{13}$ ,  $R^{15}$ , and  $R^{16}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

$R^{14}$  is hydrogen, aryl or hetaryl;

G is  $-O-(CH_2)_k-R^{17}$ ,




wherein  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{21}$  independently from each other are hydrogen, halogen, aryl, hetaryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy;

$k$  is 0, 1 or 2;

J is  $-O-(CH_2)_l-R^{22}$ ,

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 6 of 25



wherein  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$  and  $R^{26}$  independently from each other are hydrogen, halogen, aryl, hetaryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy;

$l$  is 0, 1 or 2;

$a$  is 0, 1, or 2;

$b$  is 0, 1, or 2;

$c$  is 0, 1, or 2;

$d$  is 0 or 1;

$e$  is 0, 1, 2, or 3;

$f$  is 0 or 1;

$R^5$  is hydrogen or  $C_{1-6}$ -alkyl optionally substituted with one or more hydroxyl, aryl or hetaryl;

$R^6$  and  $R^7$  are independently from each other hydrogen or  $C_{1-6}$ -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;

$R^8$  is hydrogen or  $C_{1-6}$ -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;

$R^6$  and  $R^7$  or  $R^6$  and  $R^8$  or  $R^7$  and  $R^8$  may optionally form  $-(CH_2)_i-U-(CH_2)_j-$ , wherein  $i$  and  $j$

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 7 of 25

independently from each other are 1, 2 or 3 and U is -O-, -S-, or a valence bond;

M is arylenc, hetarylene, -O-, -S- or  $-\text{CR}^{27}=\text{CR}^{28}-$ ;


$\text{R}^{27}$  and  $\text{R}^{28}$  are independently from each other hydrogen or  $\text{C}_{1-6}$ -alkyl, optionally substituted with one or more aryl or hetaryl;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1 wherein  $\text{R}^1$  is  $\text{C}_{1-6}$ -alkyl.

3. (Original) The compound of claim 1 wherein  $\text{R}^2$  is  $\text{C}_{1-6}$ -alkyl.

4. (Currently amended) The compound of claim 1 wherein L is



wherein  $\text{R}^4$  is hydrogen or  $\text{C}_{1-6}$  alkyl;

$p$  is 0 or 1;

$q$ ,  $s$ ,  $t$ ,  $u$  are independently from each other 0, 1, 2, 3 or 4;

$r$  is 1;


Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 8 of 25

the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

$R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

Q is  $>N-R^{13}$  or




wherein  $o$  is 0, 1 or 2;

$T$  is  $-N(R^{15})(R^{16})$  or hydroxyl;

$R^{13}$ ,  $R^{15}$ , and  $R^{16}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl; and

$R^{14}$  is hydrogen, aryl or hetaryl.

5. (Original) The compound of claim 1 wherein L is



wherein  $q$ ,  $s$ ,  $t$ ,  $u$  are independently from each other 0, 1, 2, 3 or 4;

$r$  is 0 or 1;


the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 9 of 25

$R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

Q is  $>N-R^{13}$  or




wherein o is 0, 1 or 2;

T is  $-N(R^{15})(R^{16})$  or hydroxyl;

$R^{13}$ ,  $R^{15}$ , and  $R^{16}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl; and

$R^{14}$  is hydrogen, aryl or hetaryl.

6. (Original) The compound of claim 1 wherein G is




wherein  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{21}$  independently from each other are hydrogen, halogen, aryl, hetaryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy.

7. (Original) The compound of claim 1 wherein J is

Attorney Docket No. 5573.210-US  
Application No. 09/356.313

August 10, 2007  
Page 10 of 25




wherein  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$  and  $R^{26}$  independently are hydrogen, halogen, aryl, heteraryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy.

8. (Original) The compound of claim 1 wherein M is arylene or  $-CR^{27}=CR^{28}-$ , wherein  $R^{27}$  and  $R^{28}$  independently are hydrogen or  $C_{1-6}$ -alkyl, optionally substituted with aryl or heteraryl.
9. (Original) The compound of claim 1 wherein  $R^6$  and  $R^7$  independently from each other are hydrogen or  $C_{1-6}$ -alkyl.
10. (Original) The compound of claim 1 wherein  $R^6$  and  $R^7$  form  $-(CH_2)_i-U-(CH_2)_j-$ , wherein i and j independently from each other are 1, 2 or 3 and U is  $-O-$ ,  $-S-$ , or a valence bond.
11. (Original) The compound of claim 1 wherein  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl.
12. (Previously presented) The compound of claim 1 selected from  
  
(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
Application No. 09/356,313


August 10, 2007  
Page 11 of 25



(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((3S)-3-(dimethylaminomethyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((3S)-3-(dimethylaminomethyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 12 of 25

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((2S)-2-((dimethylamino)methyl)pyrrolidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




N-((1R)-1-{N-[(1R)-1-Benzyl-2-((2S)-2-((dimethylamino)methyl)pyrrolidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methyl-3-((methylamino)methyl)benzamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-(dimethylamino)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
Application No. 09/356.313


August 10, 2007  
Page 13 of 25



(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-[(1R)-1-(N-methyl-N-[(1R)-1-[N-methyl-N-(1-methylpiperidin-4-yl)carbamoyl]-2-phenylethyl]carbamoyl]-2-(2-naphthyl)ethyl]amide




3-Aminomethyl-N-[(1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl]-N-methylbenzamide




Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 14 of 25

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




**(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)amide**




**3-Aminomethyl-N-methyl-N-((1R)-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)benzamide**

Attorney Docket No. 5573.210-US  
Application No. 09/356,313


August 10, 2007  
Page 15 of 25



(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)amide



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




August 10, 2007  
Page 16 of 25

CN(C)C(=O)C(Cc1ccccc1)C(=O)N(C)C(=O)C(Cc2cc3ccccc3cc2)[C@H](C)C/C=C/C(C)(C)CNCN(C)C(=O)[C@H](Cc1ccc(cc1)-c2ccccc2)C(=O)N(C)C/C=C/C3(CCC3)N


PAGE 17/26 \* RCVD AT 8/10/2007 11:17:12 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/19 \* DNIS:2738300 \* CSID:6099875440 \* DURATION (mm-ss):02-26

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 17 of 25




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 18 of 25



(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 19 of 25




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 20 of 25




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxy-4-(2-thienyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(3-hydroxycyclohexylcarbamoyl)-2-phenylethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
Application No. 09/356.313


August 10, 2007  
Page 21 of 25



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-(dimethylamino)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 22 of 25

(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(biphenyl-4-yl)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-2-(biphenyl-4-yl)-1-{N-[(1R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 23 of 25




(2E)-5-Methyl-5-(methylamino)hex-2-enoic acid N-((1R)-1-(N-((1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl)-2-(biphenyl-4-yl)ethyl)-N-methylamide



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid ((1R)-1-(N-((1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)-N-methylcarbamoyl)-2-(biphenyl-4-yl)ethyl)amide, or

Attorney Docket No. 5573.210-US  
Application No. 09/356,313

August 10, 2007  
Page 24 of 25



and pharmaceutically acceptable salts thereof.

13. (Original) A method of treating growth retardation in connection with asthma, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
14. (Original) The method of claim 13, wherein the compound is a growth hormone secretagogue.
15. (Previously presented) A composition comprising, as an active ingredient, a compound of claim 1 together with a pharmaceutically acceptable carrier or diluent.
16. (Original) A method of stimulating the release of growth hormone from the pituitary of a mammal, the method comprising administering to the mammal an effective amount of a compound of claim 1 or a composition of claim 15.
17. (Original) A method of treating growth retardation in connection with juvenile rheumatic

Attorney Docket No. 5573.210-US  
Application No. 09/356.313

August 10, 2007  
Page 25 of 25

arthritis or systic fibrosis, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

18. (Cancelled)